Monovalent modified mRNA influenza vaccine - Sanofi
Alternative Names: H3 mRNA LNP vaccine - Sanofi; Influenza haemagglutinin mRNA vaccine - Sanofi; Monovalent mRNA vaccine - SanofiLatest Information Update: 24 May 2024
Price :
$50 *
At a glance
- Originator Sanofi
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Influenza virus infections
Most Recent Events
- 14 Mar 2024 Sanofi completes a phase I trial in Influenza virus infections (Prevention) in Australia and United Kingdom (IM) (NCT05829356)
- 17 Apr 2023 Phase-I clinical trials in Influenza virus infections (Prevention) in Australia (IM) (NCT05829356)